Mauritania
Tuberculosis profile
Population  2012 3.8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.5 (1.3–6.9) 93 (34–181)
Mortality (HIV+TB only) 0.36 (0.31–0.41) 9.5 (8.2–11)
Prevalence  (includes HIV+TB) 30 (14–52) 794 (373–1 370)
Incidence  (includes HIV+TB) 13 (11–16) 350 (288–418)
Incidence (HIV+TB only) 0.57 (0.47–0.68) 15 (12–18)
Case detection, all forms (%) 20 (16–24)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 522 (61) Relapse 112 (85)
Smear-negative 354 (14) Treatment after failure 20 (15)
Smear-unknown / not done 0 (0) Treatment after default 0 (0)
Extrapulmonary 628 (25) Other 0 (0)
Other 0 (0)      
Total new 2 504   Total retreatment 132  
           
Other (history unknown) 0        
Total new and relapse 2 616   Total cases notified 2 636  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.4 2.6 1.9
Age < 15 47 15 23
Laboratories 2012
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 1.3
Drug susceptibility testing (per 5 million population) 1.3
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 73   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 66  
Retreatment 53  
TB/HIV 2012 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
34 (2–64) 25 (10–41)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 1 (<1%)   1
Laboratory-confirmed MDR-TB cases 1   1
Patients started on MDR-TB treatment     1
Financing TB control 2013
National TB programme budget (US$ millions) 1
% Funded domestically 39%
% Funded internationally  
% Unfunded 61%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data